Investasi
Fitur
BiayaKeamanan
Akademi
Lainnya
Pluang+

Bandingkan Harga & Kinerja Organon Pharma Indonesia Tbk. (SCPI) vs Wismilak Inti Makmur Tbk. (WIIM)

Organon Pharma Indonesia Tbk.Trading
Wismilak Inti Makmur Tbk.Trading

Kinerja harga (24 Jam Terakhir)

Statistik utama

Perbedaan Organon Pharma Indonesia Tbk. dan Wismilak Inti Makmur Tbk.: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Wismilak Inti Makmur Tbk. diperdagangkan di Rp1.615 (kapitalisasi pasar 3,32 T, volume 24 jam 1,5 jt). Perbedaan utamanya: Wismilak Inti Makmur Tbk. jauh lebih besar — sekitar 31,8× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.

SCPIWIIM
Kapitalisasi Pasar
104,4 M3,32 T
Volume
1,5 jt
Lot
14,97 rb
Perputaran
2,37 M
Harga Rata-rata
1.585,03
Nilai Transaksi
2,37 M
Harga Ekuilibrium Indikatif
1.615
Volume Ekuilibrium Indikatif
49

Perbandingan imbal hasil

Imbal hasil berjalan pada periode standar

Berita terkini

Berita terbaru kedua aset

SCPI
Lihat detail
WIIM
Lihat detail

Tentang Organon Pharma Indonesia Tbk.

PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.

Selengkapnya di halaman SCPI

Tentang Wismilak Inti Makmur Tbk.

PT Wismilak Inti Makmur Tbk (the Company) was established based on Notarial Deed No. 22 of Bagio Atmadja, S.H., dated December 14, 1994.

Selengkapnya di halaman WIIM